These therapeutic difficulties and failures are due to multiple mechanisms that contributes to the tumor resistance to anti-VEGF treatment, including angiogenic pathway redundancy, compensatory activation of survival signals, and pericyte and macrophage-mediated protection (132). Here, VEGFA is linked to neoplasm.